InsidersTradesSigma
Total declarations
Company
▲ Purchases (14 ops.)
▼ Sales (0 ops.)
Insider track record
ExecutiveDisclosed buys
14
Disclosed sells
0
T+90 hit rate
15%
T+90 mean return
-24.9%
Across 20 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the complete record of transactions filed by Lin Patrick, Directeur Stratégie. Insider active across 1 company, notably Processa Pharmaceuticals, Inc.. Aggregated, 23 reports have been logged. Breakdown: 14 buys · 0 sell. Total volume traded: €181k. Activity tracked since 21 June 2021. The latest transaction was filed on 27 January 2025 (Acquisition). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations23 total
14,482 sharesCommon StockSEC:0000897069-25-000795:0
43,500 shares@ US$0.797517.1% of flowCommon StockSEC:0000897069-25-000130:0
Ideal exit: 24 Oct 2025 (T+270)
1,675 sharesCommon StockSEC:0000897069-24-001611:0
1,675 sharesCommon StockSEC:0000897069-24-000921:0
2,500 shares@ US$2.372.8% of flowCommon StockSEC:0000897069-24-000236:0
Ideal exit: 27 Oct 2024 (T+270)
5,000 shares@ US$0.320.8% of flowCommon StockSEC:0000897069-23-001466:0
13,700 shares@ US$0.211.4% of flowCommon StockSEC:0000897069-23-001442:0
12,500 shares@ US$0.804.8% of flowCommon StockSEC:0001567619-23-002400:0
7,601 sharesCommon StockSEC:0001567619-22-015301:0
2,000 shares@ US$1.59450.046% mcap2.1% of flowCommon StockSEC:0001567619-22-011300:0
Ideal exit: 11 Feb 2023 (T+270)
1,200 shares@ US$3.12670.053% mcap2.4% of flowCommon StockSEC:0001567619-22-008312:0
Ideal exit: 1 Jan 2023 (T+270)
3,000 shares@ US$4.005.5% of flowCommon StockSEC:0001567619-22-000291
Ideal exit: 10 Sept 2022 (T+270)
3,000 shares@ US$4.000.16% mcap7.5% of flowCommon StockSEC:0001567619-22-000291:0
Ideal exit: 10 Sept 2022 (T+270)
3,000 shares@ US$4.005.5% of flowCommon StockSEC:0001567619-21-022195
Ideal exit: 10 Sept 2022 (T+270)
3,000 shares@ US$4.000.16% mcap7.5% of flowCommon StockSEC:0001567619-21-022195:0
Ideal exit: 10 Sept 2022 (T+270)
3,500 shares@ US$4.79867.6% of flowCommon StockSEC:0001567619-21-021708
Ideal exit: 30 Aug 2022 (T+270)
3,500 shares@ US$4.79860.23% mcap10.5% of flowCommon StockSEC:0001567619-21-021708:0
Ideal exit: 30 Aug 2022 (T+270)
4,000 shares@ US$6.0220.31% mcap14.4% of flowCommon StockSEC:0001567619-21-016470:0
Ideal exit: 23 May 2022 (T+270)
4,000 shares@ US$6.02210.6% of flowCommon StockSEC:0001567619-21-016470
Ideal exit: 23 May 2022 (T+270)
7,601 sharesCommon StockSEC:0001567619-21-014747
7,601 sharesCommon StockSEC:0001567619-21-014747:0
2,000 shares@ US$6.655.7% of flowCommon StockSEC:0001567619-21-012486
Ideal exit: 18 Mar 2022 (T+270)
2,000 shares@ US$6.650.17% mcap7.9% of flowCommon StockSEC:0001567619-21-012486:0
Ideal exit: 18 Mar 2022 (T+270)
23 of 23 declarations
About Lin Patrick
Patrick Lin is Chief Business - Strategy Officer at Processa Pharmaceuticals, Inc. He is responsible for defining and implementing the company's business strategies. His expertise in strategic development is essential for guiding the company towards sustainable and innovative growth.
